Edition:
India

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

233.95CHF
4:53pm IST
Change (% chg)

CHF-2.05 (-0.87%)
Prev Close
CHF236.00
Open
CHF234.50
Day's High
CHF235.35
Day's Low
CHF232.55
Volume
1,566,170
Avg. Vol
1,731,617
52-wk High
CHF273.00
52-wk Low
CHF226.10

Latest Key Developments (Source: Significant Developments)

Forty Seven Inc Says Announced Deal With Genentech To Collaborate On Novel Immuno-Oncology Combination For Leukemia, Bladder Cancer
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Roche Holding Ag ::FORTY SEVEN INC SAYS ANNOUNCED DEAL WITH GENENTECH TO COLLABORATE ON NOVEL IMMUNO-ONCOLOGY COMBINATION FOR LEUKEMIA, BLADDER CANCER.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Roche Holding Ag ::SYAPSE ENTERS STRATEGIC COLLABORATION WITH ROCHE TO ADVANCE PRECISION MEDICINE IN ONCOLOGY.SYAPSE SAYS CO AND ROCHE WILL WORK JOINTLY TO DEVELOP SOFTWARE PRODUCTS AND ANALYTICS SOLUTIONS.SYAPSE SAYS ROCHE WILL FUND DEVELOPMENT OF THESE NEW PRODUCTS.SYAPSE SAYS ROCHE AND CO WILL ALSO COLLABORATE ON AUTOMATED METHODS FOR MEASURING REAL-WORLD OUTCOMES.  Full Article

Macrogenics Enters Research Collaboration With Roche
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Macrogenics Inc ::MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE.MACROGENICS INC - UNDER TERMS OF AGREEMENT, ROCHE WILL PAY MACROGENICS AN UPFRONT PAYMENT OF $10 MILLION.MACROGENICS INC - MACROGENICS WILL ALSO BE ELIGIBLE TO RECEIVE UP TO $370 MILLION IN POTENTIAL MILESTONE PAYMENTS AND ROYALTIES ON FUTURE SALES.MACROGENICS INC - FURTHER DETAILS ABOUT TRANSACTION ARE NOT DISCLOSED.MACROGENICS INC - ENTERED INTO A RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC..  Full Article

Ignyta To Commence Phase 1 Study For RXDX-106 In Early 2018
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ignyta Inc ::IGNYTA REPORTS FDA CLEARANCE OF IND FOR RXDX-106, A NOVEL IMMUNOMODULATORY AGENT AND TYRO3, AXL, MER (TAM) INHIBITOR.IGNYTA INC - COMMENCING PHASE 1 STUDY FOR RXDX-106 IN EARLY 2018.IGNYTA INC - UNDER IND, CO INTENDS TO INITIATE TARGETED IMMUNOMODULATORY TAM ANTAGONIST STUDY.  Full Article

Ignyta To Pay Roche Termination Fee Of About $58 Mln If Merger Is Terminated
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Ignyta Inc ::IGNYTA SAYS MERGER DEAL WITH ROCHE CONTAINS, UNDER CERTAIN CIRCUMSTANCES, REQUIREMENT FOR CO TO PAY ROCHE TERMINATION FEE OF ABOUT $58 MILLION - SEC FILING.  Full Article

Roche To Acquire Ignyta For $1.7 Bln
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Ignyta Inc ::ROCHE AND IGNYTA REACH DEFINITIVE MERGER AGREEMENT.IGNYTA INC SAYS ROCHE TO ACQUIRE IGNYTA FOR US$ 27.00 PER SHARE.IGNYTA INC SAYS DEAL CORRESPONDS TO A TOTAL TRANSACTION VALUE OF US$ 1.7 BILLION ON A FULLY DILUTED BASIS.IGNYTA INC SAYS MERGER AGREEMENT HAS BEEN UNANIMOUSLY APPROVED BY BOARDS OF IGNYTA AND ROCHE.  Full Article

FDA Approves Genentech's Perjeta For Post Surgery Treatment Of A Type Of Breast Cancer
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Roche Holding Ag ::FDA APPROVES GENENTECH’S PERJETA (PERTUZUMAB) FOR ADJUVANT TREATMENT OF SPECIFIC TYPE OF EARLY BREAST CANCER.GENENTECH- ‍FDA CONVERTED PREVIOUSLY GRANTED ACCELERATED APPROVAL OF PERJETA-BASED REGIMEN TO FULL APPROVAL FOR NEOADJUVANT TREATMENT OF HER2-POSITIVE​.  Full Article

Idorsia Forms Research Collaboration With Roche In Field Of Cancer Immunotherapy
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - IDORSIA LTD ::IDORSIA FORMS RESEARCH COLLABORATION WITH ROCHE IN THE FIELD OF CANCER IMMUNOTHERAPY.PARTIES WILL COLLABORATE ON DISCOVERY OF PRODUCTS THROUGH FORMATION OF A JOINT COMMITTEE, CHAIRED BY IDORSIA.ROCHE WILL PAY IDORSIA AN UPFRONT PAYMENT OF CHF 15 MILLION.ROCHE CAN THEN EXCLUSIVELY LICENSE IDORSIA COMPOUNDS AND COMPOUNDS RESULTING FROM COLLABORATION, FOR FURTHER PAYMENT OF 35 MILLION.IDORSIA WILL BE ELIGIBLE TO RECEIVE ONE-TIME DEVELOPMENT AND REGULATORY MILESTONES OF UP TO CHF 410 MILLION.IDORSIA ALSO BE ENTITLED TO ONE-TIME MILESTONES BASED ON SALES THRESHOLDS, AND TIERED ROYALTIES ON ANNUAL NET SALES.  Full Article

Confo Therapeutics Enters Into Drug Discovery Collaboration With Roche
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Confo Therapeutics::CONFO THERAPEUTICS ENTERS INTO DRUG DISCOVERY COLLABORATION WITH ROCHE.CONFO THERAPEUTICS-UNDER TERMS ROCHE GAINS RIGHTS TO COMPOUNDS RESULTING FROM COLLABORATION, WILL BE RESPONSIBLE FOR DEVELOPMENT, MANUFACTURING.CONFO THERAPEUTICS-ELIGIBLE TO RECEIVE UP TO EUR 81.5 MILLION OF PAYMENTS FOR CERTAIN DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.  Full Article

Photo

Roche's star MS medicine Ocrevus wins EU approval

ZURICH The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.